Initial evaluation of 18F-fluciclovine in prostate cancer using dynamic EXPLORER total-body PET/CT

Y Abdelhafez, L Nardo, E Leung, M Parikh, M Stephen… - 2020 - Soc Nuclear Med
1244 Purpose: 18F-fluciclovine is a radiotracer recommended for prostate cancer
biochemical recurrence assessment by the NCCN and EAU. The tracer has rapid kinetics …
Save Cite Cited by 1 Related articles
[PDF] snmjournals.orgFree from Publisher

Best practices for 18F-fluciclovine PET/CT imaging of recurrent prostate cancer: a guide for technologists

FI Tade, RA Sajdak, M Gabriel… - Journal of Nuclear …, 2019 - Soc Nuclear Med
18F-fluciclovine is a Food and Drug Administration–approved PET tracer indicated for
patients suspected to have recurrent prostate cancer based on a prostate-specific antigen …
Save Cite Cited by 13 Related articles All 5 versions
[HTML] mdpi.com

[HTML][HTML] Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer

T Bach-Gansmo, K Korsan, TV Bogsrud - Tomography, 2022 - mdpi.com
Background: 18F-fluciclovine is a positron emission tomography (PET) radiotracer approved
for the detection of prostate cancer recurrence. No effect of androgen deprivation therapy …
Save Cite Cited by 1 Related articles All 7 versions Cached

Detection rates from 18f-fluciclovine total-body PET/CT in prostate cancer patients with biochemical recurrence

Y Abdelhafez, S Azghadi, B Spencer, C Evans… - 2022 - Soc Nuclear Med
3042 Introduction: 18 F-fluciclovine, a synthetic amino acid approved for assessment of
biochemically recurrent prostate cancer (BCR PCa), has rapid kinetics and was shown to …
Save Cite Cited by 2 Related articles
[PDF] ntnu.no

A PET/MRI study towards finding the optimal [18F]Fluciclovine PET protocol for detection and characterisation of primary prostate cancer

M Elschot, KM Selnæs, E Sandsmark… - European journal of …, 2017 - Springer
Abstract Purpose [18 F] Fluciclovine PET imaging shows promise for the assessment of
prostate cancer. The purpose of this PET/MRI study is to optimise the PET imaging protocol …
Save Cite Cited by 31 Related articles All 10 versions
[PDF] clinicaltrials.gov

[PDF][PDF] Protocol Title: 18F‐Fluciclovine PET CT as an indicator of therapeutic response in metastatic prostate carcinoma (M1PCa).

GC Ravizzini, TK Bathala, H Macapinlac, K Hoffman… - classic.clinicaltrials.gov
3.0 Study Objective Primary objective: Evaluate metabolic response by 18F‐fluciclovine PET
qualitatively and semi‐quantitatively with standardized uptake values (SUV) following …
Save Cite Related articles View as HTML
[HTML] mdpi.com

[HTML][HTML] [18F]Fluciclovine PET/CT Improves the Clinical Management of Early Recurrence Prostate Cancer Patients

AG Nappi, C Ferrari, P Mammucci, D Rubini, V Lavelli… - Cancers, 2022 - mdpi.com
Simple Summary In the challenge between increasingly sensitive PET radiopharmaceuticals
for the evaluation of prostate cancer patient in biochemical relapse, the choice of the most …
Save Cite Cited by 4 Related articles All 9 versions Cached
[HTML] nature.com

[HTML][HTML] 18F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review

S Rais-Bahrami, JA Efstathiou, CM Turnbull… - Prostate Cancer and …, 2021 - nature.com
Background A systematic literature review of the performance of 18Fluorine-fluciclovine
PET/CT for imaging of men with recurrent prostate cancer was performed. Methods Scientific …
Save Cite Cited by 17 Related articles All 7 versions
[PDF] redjournal.org

Detectability rates and impact on management from high-sensitivity Total-body 18F-Fluciclovine PET/CT scans in patients with prostate cancer biochemical recurrence

S Azghadi, Y Abdelhafez, M Parikh… - International Journal of …, 2021 - redjournal.org
Purpose/Objective (s) 18 F-fluciclovine, an FDA-approved synthetic amino acid
radiopharmaceutical for assessment of prostate cancer (PCa) recurrence, may show modest …
Save Cite Cited by 4 Related articles All 3 versions

Multisite experience of fluciclovine (18F) PET/CT imaging in biochemically recurrent prostate cancer: Impact of clinical factors and intersite variation.

L Zanoni, C Nanni, T Bach-Gansmo, TV Bogsrud… - 2017 - ascopubs.org
163 Background: Fluciclovine (18F) is an FDA-approved positron emission tomography/
computerized tomography (PET/CT) tracer in clinical use for the detection and localization of …
Save Cite Cited by 2 Related articles